Navigation Links
Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
Date:11/7/2009

MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. The results come from a self-reported survey of patients conducted in parallel with the ongoing, prospective, open label International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T. 2) for C1-INH concentrate. Of the patients surveyed, 98.3 percent reported satisfaction with the treatment, with 37 percent responding that without C1-INH they would have sought emergency treatment and 43 percent would have deferred any medical therapy.

Twenty-eight patients participated in the self-reported survey with responses collected via home computer or telephone voice response. Before the study, these patients reported an annual average of three emergency room visits and four hospital days due to acute attacks. Over 29 months, participants reported 384 attacks (261 abdominal, 71 extremities, eight facial, six genitourinary, 17 laryngeal, and 21 other) with a median of three per patient. C1-INH was used to treat approximately 71 percent of reported attacks. From the start of the attack to C1-INH dosing, the mean time was 12.1 hours (ranging from 0.0 to 189.8 hours) and the mean time from start of treatment to onset of symptom relief was 1.07 hours (ranging from 0.0 to 25.3 hours). The mean time to complete resolution was 18.4 hours (ranging from 1.22 to 471.7 hours).

"Recognizing an acute attack in its early stages is vital in successfully managing the disease," said Robyn J. Levy, M.D., of the Family Allergy & Asthma Center in Atlanta, GA, and the lead investigator of the study. "This survey shows that patients found C1-INH replac
'/>"/>

SOURCE CSL Behring
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies
7. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
8. Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)...  EP Global Communications, Inc. (Public OTC: EPGL) announced today ... Company about discussing EPGL,s electronic contact lens technologies.  ... 3, 2015.  Novartis CEO Joe Jimenez ... electronic contact lens market could be worth tens ... years.  Novartis partnered with Google in 2014 to ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm ... it has acquired a majority interest in Salter Labs ... a leading manufacturer of disposable respiratory and sleep diagnostics ... care markets.   "Salter represents an exciting ...
... Talecris Biotherapeutics (Nasdaq: TLCR ) announced ... Inhibitor [Human])(A1PI), a more concentrated and purified formulation of ... Canada for more than 20 years.  PROLASTIN-C delivers twice ... infusion volume and time in half when given at ...
Cached Medicine Technology:RoundTable Healthcare Partners Acquires Majority Stake in Salter Labs 2RoundTable Healthcare Partners Acquires Majority Stake in Salter Labs 3Talecris Biotherapeutics Launches PROLASTIN®-C in Canada 2Talecris Biotherapeutics Launches PROLASTIN®-C in Canada 3Talecris Biotherapeutics Launches PROLASTIN®-C in Canada 4Talecris Biotherapeutics Launches PROLASTIN®-C in Canada 5
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it is ... campus. The goal is to bring this Torah – dating from 1880 – back ... and religious services. , Scroll No. 515, from the town of Taus-Domazlice, is ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the network ... their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been ... companies have agreed to join their missions of purpose together to change the course ...
(Date:8/1/2015)... , ... August 01, 2015 , ... On Tuesday, July ... , who are thought to have been behind the attack on Anthem Inc. which ... were zero day exploits, watering hole attacks and spear phishing campaigns. , ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe ... the very first small business donation to kick off the campaign for healing and ... Her legacy includes a complete line of raw, organic hair care products, as well ...
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, Phil ... reached Connecticut and was greeted by friends and family. He visited CCAR and left ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:March4thforWellBeing Foundation Kickoff 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... begun full-parity plans ahead of deadline; new case studies ... reports the majority of its customers are revamping their ... Act, and that a significant amount already have gone ... 1, 2010. ComPsych Corporation is the world,s largest provider ...
... University of Leeds are working on a new type of body ... cement with recycled carbon fibre materials to make a material tough ... project, still at the early research stage, is being carried out ... Philip Purnell, who is leading the team, said: "By using cement ...
... Improves Patient Care with Automatic Access to Radiology Reports ... a division of Conceptual MindWorks, Inc. (CMI), today announced ... Radiological Association,s (ARA) radiology reports. ARA is one of ... operates 14 outpatient radiology clinics in addition to providing ...
... Innovative new concept caters to active baby-boomer retirees , ... of America (ORCA) has started taking reservations for a program ... private residential cruise ship that also provides both the Independent ... , "People retire to Florida for three things mainly ...
... , CHICAGO, June 29 Rising Financial ... of Rising Medical Solutions, Inc., is pleased to announce ... Business Development for its Medicare Set Aside (MSA) Administration ... , , Abdelsayed joins Rising Financial Solutions (Rising) ...
... , Italy, June 29 Health-Robotics today announced,that ... with Grifols,S.A., the leading Pharmacy Automation provider in ... accurately, and cost-effectively automate,the preparation of non-hazardous IV ... this strategic partnership, Grifols will take,delivery of 120 ...
Cached Medicine News:Health News:Mental Health Parity Act Spurs Early Action Among Employers 2Health News:Sevocity Launches EHR (Electronic Health Record) Interface With Austin Radiological Association 2Health News:Sevocity Launches EHR (Electronic Health Record) Interface With Austin Radiological Association 3Health News:Retirement Cruise Ship Nearing Launch 2Health News:Rising Financial Solutions Taps Director of Business Development for Medicare Set Aside Administration Offerings 2Health News:Health Robotics Announces i.v.STATION(TM) Contract With Grifols in Spain, Portugal and South America 2Health News:Health Robotics Announces i.v.STATION(TM) Contract With Grifols in Spain, Portugal and South America 3
... Nephew ECTRA II systems permit the surgeon ... ligament endoscopically, allowing access via two portals ... endoscopic lens fogging with good air flow. ... and control. ECTRA knives permit the surgeon ...
... Screw System provides a unique option for the ... particularly the opening wedge osteotomy of the first ... Fragment Plate and Screw Set is a complete ... houses the plates, screws, and drills. It provides ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Medicine Products: